1. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases 
Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi, Francesco Montorsi, Shahrokh Shariat, Bernhard Grubmüller, Giorgio Gandaglia, Alberto Briganti, R. Jeffrey Karnes 
European Urology Oncology 
Volume 1, Issue 1, Pages (May 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Overall survival for the cohort of 113 patients. CE=cumulative number of events; NR=number at risk.
European Urology Oncology 2018 1, 46-53DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Clinical relapse-free survival. CE=cumulative number of events; NR=number at risk.
European Urology Oncology 2018 1, 46-53DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Overall survival according to serum PSA<0.1ng/ml versus >0.1ng/ml at 6 wk after surgery (p=0.0003). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen.
European Urology Oncology 2018 1, 46-53DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

5. Fig. 4
PSA relapse-free survival according to preoperative PSA<1.0ng/ml versus 1.1–4.0ng/ml versus>4.1ng/ml (p=0.0004). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen.
European Urology Oncology 2018 1, 46-53DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

6. Fig. 5
PSA relapse-free survival according to median preoperative PSA<8.0ng/ml versus >8.0ng/ml (p=0.002). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen.
European Urology Oncology 2018 1, 46-53DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions